Phase II study of adjuvant therapy of alternate day oral therapy with S-1 for patients with curative resected biliary tract cancer
Not Applicable
- Conditions
- biliary tract cancer
- Registration Number
- JPRN-UMIN000021459
- Lead Sponsor
- Gastrointestinal and pediatric surgery Tokyo medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) administration contraindication of TS-1 2)Regular use of frucitocin, fenitoin, warfarin 3) Severe infection 4) Intestinal pneumonia or lung fibrosis 5) Severe diarrhea 6) Severe complication 7) History of other active malignancy 8) Pregnancy or the desire to preserve fecundity 9) Inadequate physical condition, as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method